Selected research
Industry Growth & Trends
Global cfDNA Testing Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global cfDNA Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for cfDNA Testing is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for cfDNA Testing is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for cfDNA Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the cfDNA Testing market include Illumina, Oncogenomics, Revvity, CareDx, Natera, BillionToOne, Inc., Yourgene Health, ARUP Laboratories and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global cfDNA Testing market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The cfDNA Testing market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global cfDNA Testing market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to cfDNA Testing.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global cfDNA Testing market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
cfDNA Testing Market by Company
Illumina
Oncogenomics
Revvity
CareDx
Natera
BillionToOne, Inc.
Yourgene Health
ARUP Laboratories
Roche
cfDNA Testing Segment by Type
Targeted Sequencing
Whole Genome Sequencing
cfDNA Testing Segment by Application
Prenatal Testing
Oncology
Organ Transplant Monitoring
Others
cfDNA Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global cfDNA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of cfDNA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of cfDNA Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of cfDNA Testing companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Sequencing
- Whole Genome Sequencing
Applications
- Prenatal Testing
- Oncology
- Organ Transplant Monitoring
- Others
Companies covered
- Illumina
- Oncogenomics
- Revvity
- CareDx
- Natera
- BillionToOne, Inc.
- Yourgene Health
- ARUP Laboratories
- Roche
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global cfDNA Testing Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global cfDNA Testing Market Size by Region (2021-2032)
- 1.4.1 Global cfDNA Testing Market Size by Region (2021-2026)
- 1.4.2 Global cfDNA Testing Market Size by Region (2027-2032)
- 1.5 Key Regions cfDNA Testing Market Size (2021-2032)
- 1.5.1 North America cfDNA Testing Market Size Growth Rate (2021-2032)
- 1.5.2 Europe cfDNA Testing Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific cfDNA Testing Market Size Growth Rate (2021-2032)
- 1.5.4 South America cfDNA Testing Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa cfDNA Testing Market Size Growth Rate (2021-2032)
2 cfDNA Testing Market by Type
- 2.1 Type Introduction
- 2.1.1 Targeted Sequencing
- 2.1.2 Whole Genome Sequencing
- 2.2 Global cfDNA Testing Market Size by Type
- 2.2.1 Global cfDNA Testing Market Size Overview by Type (2021-2032)
- 2.2.2 Global cfDNA Testing Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global cfDNA Testing Market Size Forecasted by Type (2027-2032)
- 2.3 Global cfDNA Testing Market Size by Regions
- 2.3.1 North America cfDNA Testing Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe cfDNA Testing Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific cfDNA Testing Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America cfDNA Testing Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa cfDNA Testing Market Size Breakdown by Type (2021-2026)
3 cfDNA Testing Market by Application
- 3.1 Type Introduction
- 3.1.1 Prenatal Testing
- 3.1.2 Oncology
- 3.1.3 Organ Transplant Monitoring
- 3.1.4 Others
- 3.2 Global cfDNA Testing Market Size by Application
- 3.2.1 Global cfDNA Testing Market Size Overview by Application (2021-2032)
- 3.2.2 Global cfDNA Testing Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global cfDNA Testing Market Size Forecasted by Application (2027-2032)
- 3.3 Global cfDNA Testing Market Size by Regions
- 3.3.1 North America cfDNA Testing Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe cfDNA Testing Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific cfDNA Testing Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America cfDNA Testing Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa cfDNA Testing Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 cfDNA Testing Industry Trends
- 4.2 cfDNA Testing Industry Drivers
- 4.3 cfDNA Testing Industry Opportunities and Challenges
- 4.4 cfDNA Testing Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by cfDNA Testing Revenue (2021-2026)
- 5.2 Global cfDNA Testing Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global cfDNA Testing Key Company Headquarters & Area Served
- 5.4 Global cfDNA Testing Company, Product Type & Application
- 5.5 Global cfDNA Testing Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global cfDNA Testing Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 cfDNA Testing Players Market Share by Revenue in 2025
- 5.6.3 2025 cfDNA Testing Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Illumina
- 6.1.1 Illumina Company Information
- 6.1.2 Illumina Business Overview
- 6.1.3 Illumina cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Illumina cfDNA Testing Product Portfolio
- 6.1.5 Illumina Recent Developments
- 6.2 Oncogenomics
- 6.2.1 Oncogenomics Company Information
- 6.2.2 Oncogenomics Business Overview
- 6.2.3 Oncogenomics cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Oncogenomics cfDNA Testing Product Portfolio
- 6.2.5 Oncogenomics Recent Developments
- 6.3 Revvity
- 6.3.1 Revvity Company Information
- 6.3.2 Revvity Business Overview
- 6.3.3 Revvity cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Revvity cfDNA Testing Product Portfolio
- 6.3.5 Revvity Recent Developments
- 6.4 CareDx
- 6.4.1 CareDx Company Information
- 6.4.2 CareDx Business Overview
- 6.4.3 CareDx cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 CareDx cfDNA Testing Product Portfolio
- 6.4.5 CareDx Recent Developments
- 6.5 Natera
- 6.5.1 Natera Company Information
- 6.5.2 Natera Business Overview
- 6.5.3 Natera cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Natera cfDNA Testing Product Portfolio
- 6.5.5 Natera Recent Developments
- 6.6 BillionToOne, Inc.
- 6.6.1 BillionToOne, Inc. Company Information
- 6.6.2 BillionToOne, Inc. Business Overview
- 6.6.3 BillionToOne, Inc. cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 BillionToOne, Inc. cfDNA Testing Product Portfolio
- 6.6.5 BillionToOne, Inc. Recent Developments
- 6.7 Yourgene Health
- 6.7.1 Yourgene Health Company Information
- 6.7.2 Yourgene Health Business Overview
- 6.7.3 Yourgene Health cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Yourgene Health cfDNA Testing Product Portfolio
- 6.7.5 Yourgene Health Recent Developments
- 6.8 ARUP Laboratories
- 6.8.1 ARUP Laboratories Company Information
- 6.8.2 ARUP Laboratories Business Overview
- 6.8.3 ARUP Laboratories cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 ARUP Laboratories cfDNA Testing Product Portfolio
- 6.8.5 ARUP Laboratories Recent Developments
- 6.9 Roche
- 6.9.1 Roche Company Information
- 6.9.2 Roche Business Overview
- 6.9.3 Roche cfDNA Testing Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Roche cfDNA Testing Product Portfolio
- 6.9.5 Roche Recent Developments
7 North America
- 7.1 North America cfDNA Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America cfDNA Testing Market Size by Country (2021-2026)
- 7.3 North America cfDNA Testing Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe cfDNA Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe cfDNA Testing Market Size by Country (2021-2026)
- 8.3 Europe cfDNA Testing Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific cfDNA Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific cfDNA Testing Market Size by Country (2021-2026)
- 9.3 Asia-Pacific cfDNA Testing Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America cfDNA Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America cfDNA Testing Market Size by Country (2021-2026)
- 10.3 South America cfDNA Testing Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa cfDNA Testing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa cfDNA Testing Market Size by Country (2021-2026)
- 11.3 Middle East & Africa cfDNA Testing Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst